A015540 Stock Overview
THELMA Therapeutics Co., Ltd. operates as a biopharmaceutical company in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
THELMA Therapeutics Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩70.00 |
| 52 Week High | ₩300.00 |
| 52 Week Low | ₩55.00 |
| Beta | 0.26 |
| 1 Month Change | -98.91% |
| 3 Month Change | -98.91% |
| 1 Year Change | n/a |
| 3 Year Change | -98.99% |
| 5 Year Change | -99.05% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| A015540 | KR Media | KR Market | |
|---|---|---|---|
| 7D | -6.7% | -6.0% | -1.5% |
| 1Y | n/a | -23.7% | -10.9% |
Return vs Industry: Insufficient data to determine how A015540 performed against the KR Media industry.
Return vs Market: Insufficient data to determine how A015540 performed against the KR Market.
Price Volatility
| A015540 volatility | |
|---|---|
| A015540 Average Weekly Movement | 35.9% |
| Media Industry Average Movement | 6.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.8% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A015540's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine A015540's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 4 | Lee Kyu | thelma.co.kr |
THELMA Therapeutics Co., Ltd. operates as a biopharmaceutical company in South Korea and internationally. The company develops TLM-01, a non-alcoholic steatohepatitis drug; TLM-02, an antiviral agent for COVID-19; TLM-03/TLM-04, an anticancer drug for solid and blood cancer; and TLM-05, a liver cancer drug. It also offers radioembolization and brachytherapy devices for the cancer treatments.
THELMA Therapeutics Co., Ltd. Fundamentals Summary
| A015540 fundamental statistics | |
|---|---|
| Market cap | ₩4.37b |
| Earnings (TTM) | -₩3.36b |
| Revenue (TTM) | ₩6.51b |
0.7x
P/S Ratio-1.3x
P/E RatioIs A015540 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A015540 income statement (TTM) | |
|---|---|
| Revenue | ₩6.51b |
| Cost of Revenue | ₩6.45b |
| Gross Profit | ₩52.97m |
| Other Expenses | ₩3.42b |
| Earnings | -₩3.36b |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -53.91 |
| Gross Margin | 0.81% |
| Net Profit Margin | -51.67% |
| Debt/Equity Ratio | 10.7% |
How did A015540 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/11/07 08:46 |
| End of Day Share Price | 2023/11/06 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
THELMA Therapeutics Co., Ltd. is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|